Neurocrine gains BIAL’s Parkinson’s asset Opicapone for North America

By Vipul Sikka

Pharma Deals Review: Vol 2017 Issue 4 (Table of Contents)

Published: 5 Apr-2017

DOI: 10.3833/pdr.v2017.i4.2234     ISSN: 1756-7874

Section: Licensing



To add to its neurological disorders portfolio, Neurocrine has entered into a licensing agreement with BIAL for the development and commercialisation of the latter’s Parkinson’s disease asset, opicapone (Ongentys®)...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details